Adagene Inc.

ADAG | NASDAQ

Price Alert Chart Builder DCF Calculator

$3.21

-$0.10 (-3.02%)

At close: Sep 21, 2026, 4:00 PM ET

$3.20

-$0.01 (-0.31%)

Pre-market: Sep 22, 2026, 8:12 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-3.02%

(1D)

Rating

Updated: Aug 22, 2026

33.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $120.85M

1D Range

3.18 3.31

52W Range

1.30 4.85

Valuation (TTM)

PE -6.83

PB 1.14

EV/EBITDA 0.04

Valuation (NTM)

Forward PE N/A

Forward PEG -0.23

Price Target $8.67

Cash Flow

FCF Yield -16.1%

SBC Adj. FCF Yield -16.1%

SBC Impact N/A

Margins

Gross Margin 94.2%

Operating Margin -240.3%

FCF Margin -209.0%

Growth (CAGR)

Revenue 3Y | 5Y -21.3% | 63.8%

Dil EPS 3Y | 5Y 36.4% | 41.1%

FCF 3Y | 5Y -83.5% | -50.0%

Returns

ROA -15.4%

ROE -29.1%

ROIC -19.6%

Financial Health

Net Cash

$122.01M

Current Ratio 5.02

Interest Coverage -78.34

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineere...

Sector Healthcare

Industry Biotechnology

Employees 128

IPO Date Feb 8, 2021

Website www.adagene.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

Upside

+180.37%

Buy (2)

Hold (0)

Sell (0)

Analyst Details ➞